Overall Survival (OS) for mCRPC patients treated with docetaxel for a... | Download Scientific Diagram
mCRPC: PREVAIL Trial | HCP Site | XTANDI® (enzalutamide)
Optimal sequencing of commonly used medications for treatment of metastatic castration-resistant prostate cancer - Mayo Clinic
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | NEJM
In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database - European Urology Focus
Median overall survival (in months) for patients who did not receive... | Download Scientific Diagram
The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study - ScienceDirect
Overall survival. mCRPC metastatic castration-resistant protate cancer.... | Download Scientific Diagram
Combination demonstrates encouraging results in radiographic progression-free survival in the treatment of castration-resistant metastatic prostate cancer - Onco Americas
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry | Prostate Cancer and Prostatic Diseases
IJMS | Free Full-Text | The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone
Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience | Radiation Oncology | Full Text
Overall Survival Data in mCRPC
Pattern of Clinical Progression Until Metastatic Castration-Resistant Prostate Cancer: An Epidemiological Study from the European Prostate Cancer Registry | SpringerLink
Association between CTC AR-V7 and overall survival in mCRPC. A total... | Download Scientific Diagram
ASCO GU 2022: Overall Survival after Progression on First Novel Hormonal Therapy in Patients with Metastatic Castration-Sensitive Versus Castration-Resistant Prostate Cancer (mCSPC Versus mCRPC)
Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study | In Vivo
ESMO Virtual Congress 2020: The Final Overall Survival Analysis of the PROfound Study: Olaparib vs Physician's Choice of Enzalutamide or Abiraterone in Patients with mCRPC and Homologous Recombination Repair Gene Alteration
Overall survival and second primary malignancies in men with metastatic prostate cancer | PLOS ONE
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial - ScienceDirect
Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England | Prostate Cancer and Prostatic Diseases
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry.,Prostate Cancer and Prostatic Diseases - X-MOL
A-C) Overall survival of 68 patients with metastesis castration... | Download Scientific Diagram
